Connect with us
European Gaming Congress 2024

Artificial Intelligence

Bioelectric Medicine Market Size to Hit USD 37.2 Billion at a CAGR of 6.4% by 2032

Published

on

<!– Name:DistributionId Value:8828986 –> <!– Name:EnableQuoteCarouselOnPnr Value:True –> <!– Name:IcbCode Value:2790 –> <!– Name:CustomerId Value:1269133 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:86784671-23aa-49ff-bace-4616af894f7a –>

New York, May 01, 2023 (GLOBE NEWSWIRE) — The global bioelectric medicine market size is expected to be worth around USD 37.2 Billion by 2032 from USD 20.3 Billion in 2022, growing at a CAGR of 6.4% during the forecast period from 2022 to 2032.

Bioelectric medicine also known as electroceuticals or neuromodulation is a form of bioelectric medicine. It involves the use of electrical impulses to stimulate or inhibit nervous activity. This technology is relatively young and has shown positive outcomes in treating a number of conditions including chronic pain & seizures.

The Alliance for Advancing Bioelectronic Medicine is launching the first Bioelectronic Medicine Day in January 2022. This event will include an extensive health campaign. The campaign supported efforts in the field of bioelectronics. The market is booming due to a number of factors which includes the rising prevalence and severity of chronic diseases, the demand for minimally-invasive treatments, and technological advancements. The market will boom in the future because of increased investment in bioelectric development and research.

Bioelectric Medicine Market

Get additional highlights on major revenue-generating segments, Request a Bioelectric Medicine Market sample report at https://market.us/report/bioelectric-medicine-market/request-sample/

Advertisement

Key Takeaway:

  • By product, in 2022, the bioelectric medicine market was dominated by the implantable cardioverter defibrillators segment due to an increase in severe diseases.
  • By type, the implantable electroceutical devices segment dominated the largest market share and accounted for the largest revenue share in the bioelectric medicine market in 2022.
  • By application, the arrhythmia segment dominated the largest market share.
  • By end-user type, the hospitals & clinics segment dominated the largest market share.
  • In 2022, North America dominated the market with the highest revenue share of 35%.
  • APAC is expected to grow at a greater pace owing to the growing geriatric populations in Asian countries like China & India.

Factors affecting the growth of the Bioelectric Medicine Industry

There are several factors that are affecting the growth of the bioelectric medicine industry. These include:

  • Increasing prevalence of chronic diseases: The increasing incidence of chronic diseases like diabetes, cardiovascular disease, & neurological disorders drives the demand for bioelectric medicines as effective treatments.
  • Advancements in technology: The bioelectric medicine industry is growing due to the development of advanced technologies such as implantable devices & neuromodulation therapy.
  • Increasing investment in research and development: The industry of bioelectric medicine is attracting significant investment in research & development both from the public and private sectors. This has led to the development and introduction of new therapies and devices.
  • Growing demand for non-invasive therapies: Bioelectric medicine is proving a promising option for treating numerous medical conditions.
  • Increasing awareness about the benefits of bioelectric medicine: More research is being conducted and more success cases are being shared. This is increasing awareness of the benefits of bioelectrical medicine amongst healthcare professionals and patients.

To understand how our report can bring a difference to your business strategy, Inquire about a brochure at https://market.us/report/bioelectric-medicine-market/#inquiry

Top Trends in Global Bioelectric Medicine Market

Implantable devices are the latest trend in the bioelectric medicine market for healing conditions which include chronic pain & epilepsy. Bioelectric medicine is increasingly being used in personalized medicine for targeted therapy. According to the CDC report, Cardiovascular Diseases are the main cause of death in America. CVDs may be responsible for one-fourth of deaths. More than 80% of all CVD-related deaths are owing to stroke or IHD. CVDs will cost USD 1,044 billion by 2030. The market also showcases advanced devices that are safer, more efficient, and easier to use. The InterStim Smart Programmer was used in conjunction with the InterStim system to implement sacral neuromodulation. Medtronic introduced sacral neuromodulation first and the company expected this product improvement to boost its position in the market. Strategic collaborations, mergers, and acquisitions are increasing market share.

Market Growth

Advertisement

The global bioelectric market is showcasing significant growth primarily due to the growing demand for efficient treatments of chronic diseases, technological advances in medical devices as well as increasing investments in research & development. The market is expected to surge its growth trajectory over the next few years due to factors like the increasing prevalence of neurological disorders & the adoption of non-invasive treatments as well as the growing awareness of the benefits of bioelectric medicines among patients & healthcare professionals. The emergence of new companies in the market and the growing number of partnerships & collaborations among companies are expected to further fuel the market’s growth. The bioelectric medicine industry is set to grow significantly in the next few years. It has a lot of potential for growth and innovation.

Regional Analysis

North America will be the dominant region of the global bioelectric medicines market with a market share of 35% and a projected CAGR of 7.2% over the forecast period. The growth has been surged by the presence of medical device manufacturers such as Abbott & Boston Scientific Corporation as well as a highly developed healthcare system. North America was closely followed by Europe because of the growing demand for innovative medical products. The presence of large bioelectric medicines manufacturers & a strong healthcare infrastructure is anticipated to be key driving factors for the market. The Asia Pacific region is expected to show the highest CAGR during the forecast period due to the growing geriatric population in Asian countries such as China and India. In this region, chronic diseases such as Alzheimer’s and Parkinson’s are on the rise.

Have Queries? Speak to an expert or Click Here To Download/Request a Sample

Scope of the Report

Advertisement
Report Attribute Details
Market Value (2022) USD 20.3 billion
Market Size (2032) USD 37.2 billion
CAGR (from 2023 to 2032) 6.4%
North America Revenue Share 35.0%
Historic Period 2016 to 2022
Base Year 2022
Forecast Year 2023 to 2032

Market Drivers

The global bioelectric industry is surged by numerous factors which include the increasing prevalence of chronic diseases, technological advancements, & the growing geriatric population. Other factors include rising healthcare costs, increased awareness about the benefits of bioelectric medicine, and the increasing prevalence of chronic disease. The rising incidence of chronic diseases such as cancer, diabetes, cardiovascular disease, and others has led to a huge demand for bioelectric medicine. The use of artificial intelligence & nanotechnology has led to more efficient and effective bioelectric medicine devices. The growth of bioelectric medicines is also influenced by the elderly population as there are many age-related diseases like Parkinson’s and Alzheimer’s. The market is also driven largely by increasing healthcare expenditures and the growing awareness about the benefits of bioelectric medicine.

Market Restraints

The fact that healthcare professionals do not know about the potential of bioelectric medicine can be a major obstacle to the adoption of these devices. There are also many factors that inhibit the growth of the market which include the high cost of bioelectric devices, the limited reimbursement policies, and the lack of skilled healthcare professionals. The regulatory approval process can be complex & long which can delay the release of new products. Some patients may have safety concerns about these devices and others prefer traditional medicine to bioelectric medicine. The COVID-19 epidemic has also had an impact on global bioelectric markets. This is due to disruptions in the supply chain and slowdowns of economic activities that have led to a decrease in the demand for bioelectric medical devices.

Market Opportunities

Advertisement

Global bioelectric medicine will grow rapidly in the coming years. Bioelectric medicine uses electrical signals to stimulate & regulate the body’s signaling processes. This is mainly used to treat numerous conditions which include chronic diseases, neurological disorders, & cardiovascular diseases. The market is surging due to the rising demand for noninvasive, drug-free treatments along with the growing incidence of chronic diseases & technological advancements. The bioelectric medicine market will likely see new opportunities as the industry focuses more on personalized medicines & invests more in R&D. The global bioelectric market is projected to grow significantly in the coming years.

Grow your profit margin with Market.us – Purchase This Premium Report at https://market.us/purchase-report/?report_id=101011

Report Segmentation of the Bioelectric Medicine Market

Product Insight

The bioelectric medicine market is segmented by product into implantable cardioverter-defibrillators (ICD), Cardiac Pacemakers (CP), Cochlear Implants (CI), Spinal Cord Stimulators (SCS), Deep Brain Stimulators(DBS), Sacral Nerve Stimulators(SNS), Transcutaneous Electrical Nerve Stimulators(TENS), Vagus Nerve Stimulators and Other Products. The segment of implantable cardioverter-defibrillators is the most lucrative with a projected CAGR of 6.6%. The implantable cardioverter defibrillators segment will have a revenue share of 35% by 2022. The market is expected to grow because of the increasing incidence of sudden cardiac death, an aging populace, and new product development. The deep brain stimulation market is expected to grow at an attractive rate over the forecast period due to the rising prevalence of Parkinson’s disease & lifestyle-induced disorders such as obesity and depression. In 2022, the segment of sacral nerve stimulation was responsible for a significant revenue share because of product innovation and new products.

Advertisement

Type Insight

The market is further subdivided by type into non-invasive and implantable electroceutical devices. The global bioelectric medicine industry is estimated to be dominated by implantable electroceutical devices. This segment has a market share of over 85% and a projected growth rate of 6.8% through 2022. This device was previously used to treat arrhythmias and chronic pain. It also treated depressions, tremors, and sensorineural losses. Manufacturers are focusing on launching products that meet the unmet needs of customers. In August 2018, Biotronik created a cardiac monitor named MoMe in order to improve the early diagnosis & detection of cardiac arrhythmias. The segment of noninvasive electroceutical devices is expected to surge most during the forecasted period due to technological advances and increasing investment from companies in R&D to develop innovative products.

Application Insight

According to application, the market can be divided into arrhythmias, pain management, sensorineural loss, Parkinson’s disease, tremors, treatment-resistant depression, epilepsy, urinary and fecal incontinence, and other applications. Arrhythmia with a market of 64.8% in the global bioelectric market and a projected 7.1% CAGR in 2022 is the most lucrative segment. This is due to the rising incidence of arrhythmia which involves the use of implantable cardioverter-defibrillators & cardiac pacemakers for the treatment. The epilepsy market is expected to grow at a high CAGR over the forecast period owing to the development of new treatment options such as vagus nerve stimulators. Research institutes and companies are focusing on developing innovative products. Sensorineural hearing loss is another important segment that will account for an important revenue share by 2022. This segment is primarily driven due to the growing number of patients who have hearing loss.

End User Insight

Advertisement

The market is segmented by end-user into hospitals & Clinics, ambulatory surgery centers, and other users. The hospitals & clinics segment with a revenue share of 90% is the most lucrative end-user segment in the global market for bioelectric medicine. It also has a projected CAGR (compound annual growth rate) of 7.4% over the forecast period. The growing population & improving healthcare infrastructure have fueled the demand for bioelectric medicines. Electroceuticals will be used more due to the increase in disposable income and advanced medical devices that treat severe diseases. The other segment is made up of research institutions and ambulatory surgery centers. This segment is expected to show a significant CAGR over the forecast period due to the increased investment in R&D for the development of new products.

Recent Development of the Bioelectric Medicine Market

  • Merck KGaA Darmstadt, Germany, (Merck) partnered up with Innervia Bioelectronics in July 2021 to obtain graphene-based bioelectronic Vagus nerve treatments for critical chronic disease. The partnership will use the expertise of both companies in order to develop therapies for diseases that have unmet medical needs, which are within Merck’s treatment areas.
  • Pulse Biosciences, Inc. will announce in February 2021 that the first clinic patient has been treated using the CellFX System. This first commercial use marks the beginning of the Company’s controlled release program, with product shipments made to respected dermatologists in the United States of America and Europe.

For more insights on the historical and Forecast market data from 2016 to 2032 – download a sample report at https://market.us/report/bioelectric-medicine-market/request-sample/

Market Segmentation

Based on Product

  • Implantable Cardioverter Defibrillators
  • Cardiac Pacemakers
  • Cochlear Implants
  • Spinal Cord Stimulators
  • Deep Brain Stimulators
  • Sacral Nerve Stimulators
  • Transcutaneous Electrical Nerve Stimulators
  • Vagus Nerve Stimulators
  • Other Products

Based on the Type

  • Implantable Electroceutical Devices
  • Non-invasive Electroceutical Devices

Based On the Application

  • Arrhythmia
  • Pain Management
  • Sensorineural Hearing Loss
  • Parkinson’s Disease
  • Tremor
  • Depression
  • Treatment-resistant Depression
  • Epilepsy
  • Urinary and Fecal Incontinence
  • Other Applications

Based on the End User

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Other End-Users

By Geography

  • North America
    • The US
    • Canada
    • Mexico
  • Western Europe
    • Germany
    • France
    • The UK
    • Spain
    • Italy
    • Portugal
    • Ireland
    • Austria
    • Switzerland
    • Benelux
    • Nordic
    • Rest of Western Europe
  • Eastern Europe
    • Russia
    • Poland
    • The Czech Republic
    • Greece
    • Rest of Eastern Europe
  • APAC
    • China
    • Japan
    • South Korea
    • India
    • Australia & New Zealand
    • Indonesia
    • Malaysia
    • Philippines
    • Singapore
    • Thailand
    • Vietnam
    • Rest of APAC
  • Latin America
    • Brazil
    • Colombia
    • Chile
    • Argentina
    • Costa Rica
    • Rest of Latin America
  • Middle East & Africa
    • Algeria
    • Egypt
    • Israel
    • Kuwait
    • Nigeria
    • Saudi Arabia
    • South Africa
    • Turkey
    • United Arab Emirates
    • Rest of MEA

Competitive Landscape

Major manufacturers offer numerous advanced electroceuticals via their strong distribution channels across the world. This has led to cutthroat competition between manufacturers & high pressure on pricing strategies by vendors which will affect profit margins. To capture a larger revenue share, the leading players are engaged in new product developments, collaborations, and mergers & acquisitions as well as regional expansions.

Advertisement

Some of the major players include:

  • Medtronic
  • Abbott
  • Boston Scientific Corporation
  • Cochlear Ltd.
  • LivaNova PLC
  • Biotronik SE & Co KG
  • electroCore, Inc.
  • Sonova
  • Nevro Corp.
  • Stimwave LLC
  • Other Key Players

Browse More Related Reports:

  • Nanomedicine market was valued at USD 139 Bn in 2022 and is expected to grow to USD 358 Bn in 2032. Between 2023 and 2032, this market is estimated to register the highest CAGR of 10.2%.
  • Telemedicine market size is expected to be worth around USD 590.9 Bn by 2032 from USD 63.5 Bn in 2022, growing at a CAGR of 25.7% during the forecast period from 2022 to 2032.
  • Precision medicine market size is expected to be worth around USD 254 Bn by 2032 from USD 83.4 Bn in 2022, growing at a CAGR of 12.1% during the forecast period from 2022 to 2032.
  • Sports medicine market was valued at USD 9.17 Bn in 2021. This market is projected to reach USD 18.52 Bn growing at a compound annual growth rate (CAGR) of 6.6% over the forecast period.

About Us:

Market.US (Powered by Prudour Pvt Ltd) specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicated market research report-providing firm. Market.US provides customization to suit any specific or unique requirement and tailor-makes reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons.

Follow Us On LinkedIn Facebook Twitter

Our Blog: 


Advertisement

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

SEMI Consortium to Develop Cybersecurity Strategy and Roadmap for the Semiconductor Industry in NIST Framework

Published

on

semi-consortium-to-develop-cybersecurity-strategy-and-roadmap-for-the-semiconductor-industry-in-nist-framework

MILPITAS, Calif., Sept. 30, 2024 /PRNewswire/ — Seeking to strengthen the semiconductor industry’s resilience to cybersecurity threats, the global association SEMI today announced the creation of a strategic roadmap for cybersecurity implementation throughout the industry. The SEMI Semiconductor Manufacturing Cybersecurity Consortium (SMCC) has partnered with the National Institute of Standards and Technology (NIST) to develop a semiconductor manufacturing industry profile for NIST Cybersecurity Framework 2.0 (CSF 2.0) that will serve as the foundation for the aforementioned roadmap. NIST plans to publish the profile in mid-2025. 

According to research by the Identity Theft Resource Center, cyberattacks rose by 72 percentage points in 2023 over the previous all-time high in 2021. As semiconductor factories become increasingly connected and autonomous, the industry must respond to the growing security vulnerabilities associated with this next level of digital reliance and align with broader government efforts to secure the building blocks of technologies vital to society.
“Semiconductors are integral to both national security and the global economy – we need to do everything in our power to protect the industry,” said Cherilyn Pascoe, Director of the National Cybersecurity Center of Excellence (NCCoE) at NIST. “NIST is pleased to partner with SEMI SMCC for the development and adoption of a NIST Cybersecurity Framework 2.0 Profile for Semiconductor Manufacturing. This collaboration is important to identify and reduce cybersecurity challenges in semiconductor manufacturing.”
“It’s important to recognize and address the unique cybersecurity challenges facing the semiconductor industry,” said Jennifer Lynn, SMCC Working Group Chair and Semiconductor Cybersecurity Lead at IBM Research. “This community profile could allow us to better identify and execute a path forward.”
In support of the 2023 National Cybersecurity Strategy’s strategic objective to secure global supply chains for information, communications and operational technology products and services, the White House Office of the National Cyber Director (ONCD) included a Cybersecurity Framework Profile as part of initiative 5.5.5 in the National Cybersecurity Strategy Implementation Plan Version 2. SMCC recognized the need for a cybersecurity community profile specific to semiconductor manufacturing and worked with the federal government to develop one.
“Unlike air, space, land, and sea, cyberspace is the only battle domain created entirely by human hands,” said Anjana Rajan, Assistant National Cyber Director for Technology Security at ONCD, during the Global Executive Cybersecurity Forum at SEMICON West 2024. “This means we have both the power and the responsibility to shape it. The future of cyberspace where defenders have an inherent advantage over attackers starts with preparation, and that preparation must begin with securing the building blocks.”
Prior to completion, the community profile will open for public review and commentary in accordance with NIST’s official process. The review period has yet to be announced. The community profile is part of a broader NIST strategy to further standardize cybersecurity protocols for the semiconductor sector, in line with profiles for other industries.
“With the committed resources and support from NIST to support SMCC working groups, we’ll be able to accelerate the development of this semiconductor manufacturing industry community profile creation,” said Brian Korn, Director for SMCC and Staff Technologist focused on Cybersecurity and Automation at Intel Foundry.
SMCC will provide cybersecurity recommendations for semiconductor manufacturing equipment, information on implementation, and updates on the development of the community profile. For more information, visit the project webpage or contact [email protected].
SMCC working groups are engaged with the SEMI Standards program to create a standards-based approach supporting the semiconductor ecosystem by leveraging the program’s 50-year history of industry alignment. SMCC is currently working on developments to two cybersecurity standards:
E187: Specification for Cybersecurity of Fab EquipmentE188: Specification for Malware-Free Equipment IntegrationAbout SMCC 
The Semiconductor Manufacturing Cybersecurity Consortium (SMCC) is a SEMI technology community founded in 2024 to develop and promote a standard based, semiconductor industry wide approach to improve cybersecurity and accelerate implementation of actionable solutions. The vision of SMCC is to strengthen cyber resilience and protection of the global semiconductor supply chain against evolving threats. SMCC’s reach extends all over the world and enables our members to connect and collaborate on specific cybersecurity issues and challenges affecting different regions. It focuses on important key topics and seeks to find solutions that will benefit the entire industry. 
About SEMI
SEMI® is the global industry association connecting over 3,000 member companies and 1.5 million professionals worldwide across the semiconductor and electronics design and manufacturing supply chain. We accelerate member collaboration on solutions to top industry challenges through Advocacy, Workforce Development, Sustainability, Supply Chain Management and other programs. Our SEMICON® expositions and events, technology communities, standards and market intelligence help advance our members’ business growth and innovations in design, devices, equipment, materials, services and software, enabling smarter, faster, more secure electronics. Visit  www.semi.org, contact a regional office, and connect with SEMI on LinkedIn and X to learn more. 
About NIST 
The National Institute of Standards and Technology (NIST) was founded in 1901 and is now part of the U.S. Department of Commerce. NIST is one of the nation’s oldest physical science laboratories. Congress established the agency to remove a major challenge to U.S. industrial competitiveness at the time — a second-rate measurement infrastructure that lagged behind the capabilities of the United Kingdom, Germany and other economic rivals.  
The National Cybersecurity Center of Excellence (NCCoE) under NIST is a collaborative hub where industry organizations, government agencies, and academic institutions work together to address businesses’ most pressing cybersecurity challenges. This public-private partnership enables the creation of practical cybersecurity solutions for specific industries or broad, cross-sector technology challenges. Working with technology partners—from Fortune 50 market leaders to smaller companies specializing in IT security— the NCCoE develops modular, easily adaptable example cybersecurity solutions demonstrating how to apply standards and best practices using commercially available technology. 
About ONCD
The Office of the National Cyber Director (ONCD) advises the President of the United States on cybersecurity policy and strategy. Established by Congress in 2021, ONCD is a component of the Executive Office of the President at the White House. The Office spearheaded the development of the President’s National Cybersecurity Strategy, which President Biden issued on March 2, 2023. ONCD coordinates a whole-of-government approach to implement the National Cybersecurity Strategy.
ONCD’s mission is to advance national security, economic prosperity, and technological innovation through cybersecurity policy leadership. In carrying out its directive, ONCD works closely with White House and interagency partners, as well as with all levels of government, America’s international allies and partners, non-profits, academia, and the private sector, to shape and coordinate federal cybersecurity policy. Guided by the President’s vision, as articulated in the National Cybersecurity Strategy, ONCD is working to create a more equitable, safe, and resilient interconnected world in which every American can thrive and prosper.
Association Contact Samer Bahou / SEMIPhone: 1.408.943.7870Email: [email protected]
Logo – https://mma.prnewswire.com/media/469944/Semi_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/semi-consortium-to-develop-cybersecurity-strategy-and-roadmap-for-the-semiconductor-industry-in-nist-framework-302261926.html

Continue Reading

Artificial Intelligence

MinIO Launches New MinIO Learning Subscription

Published

on

minio-launches-new-minio-learning-subscription

Unlimited access to training materials empowers enterprise customers to accelerate time-to-market for AI and data-driven applications
REDWOOD CITY, Calif., Sept. 30, 2024 /PRNewswire/ — MinIO, the leader in high-performance object storage for AI, today announced the MinIO Learning Subscription, featuring unlimited access to MinIO’s full portfolio of training content. Through the subscription, training is delivered through a combination of videos, practical exercises and hands-on labs, designed to help customers accelerate onboarding for new staff and shorten time-to-market.

The MinIO Learning Subscription learners will soon have more than 250 videos organized into courses for MinIO administrators, developers, and Kubernetes operators. The content is indexed and searchable, allowing for targeted, just-in-time performance support. Additionally, students can also choose to learn on the go using the mobile app.
“Enterprises seeking to leverage artificial intelligence and machine learning to transform their business need infrastructure at a level of scale and performance previously unthinkable,” said Pete Hnath, Head of Training and Certification at MinIO. “The MinIO Object Store is integral to reach petabyte and even exabyte scale while delivering the performance AI/ML requires. The MinIO Learning Subscription offers an accelerated on ramp to prepare teams to deploy and manage object storage at scale.”
Validation of skill transfer and job role readiness is critical for project leaders. The MinIO Learning Subscription includes a voucher for each named learner to attempt the MinIO Certified Administrator – Practitioner exam.
The MinIO Learning Subscription enables users to learn by doing with comprehensive, hands-on labs. Learners progress through lab-focused video demos, followed by hands-on guided exercises, and then outcome focused end-of-module labs to build the applied skills needed to take full advantage of MinIO’s powerful capabilities in production environments. Lab exercises can be completed on the student’s local system using basic Docker compose scripts. Subscribers also receive exclusive access to a trial license of MinIO Enterprise Object Store  to learn about features including caching, catalog, firewall, observability, and Key Management Server (KMS) that are unique to the enterprise offering.
Similarly, interacting with others is integral to the learning experience. The MinIO Learning Subscription includes an engaging peer-to-peer learning model where students can ask questions, get answers, and see others’ contributions inline with the course content. The MinIO curriculum engineers are also directly accessible to students. This provides a fluid and integrated model for collaborative learning missing from many other online learning experiences. 
Technical enablement is critical to customer success. At $700 per learner (with volume discounts available starting at just 10 learners), the MinIO Learning Subscription is priced to encourage customers to invest in their team in preparation for project success. To learn more, visit the MinIO training at https://min.io/training.
About MinIOMinIO is pioneering high-performance object storage for AI/ML and modern data lake workloads. The software-defined, Amazon S3-compatible object storage system is used by more than half of the Fortune 500. With 1.7B+ Docker downloads, MinIO is the fastest-growing cloud object storage company and is consistently ranked by industry analysts as a leader in object storage. Founded in November 2014, the company is backed by Intel Capital, Softbank Vision Fund 2, Dell Technologies Capital, Nexus Venture Partners, General Catalyst and key angel investors.
Media Contact: Tucker Hallowell, [email protected]
Logo – https://mma.prnewswire.com/media/2360095/MinIO_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/minio-launches-new-minio-learning-subscription-302261624.html

Continue Reading

Artificial Intelligence

Fourier Unveils the Next-Generation Humanoid Robot GR-2

Published

on

fourier-unveils-the-next-generation-humanoid-robot-gr-2

SHANGHAI, Sept. 30, 2024 /PRNewswire/ — Fourier, the Shanghai-based robotics company, announces the launch of GR-2, the latest addition to its GRx humanoid robot series. With remarkable upgrades across hardware, design, and software, GR-2 marks a new milestone in the field of humanoid robotics.

Next-Level Hardware Design 
GR-2 builds upon the success of its predecessor, GR-1 — the world’s first mass-produced humanoid robot. Standing at 175 cm and weighing 63 kg, GR-2 offers 53 degrees of freedom and a single-arm load capacity of 3 kg, enabling it to tackle more complex tasks.
The new robot features a detachable battery with the capacity doubled, extending runtime by an hour. This upgrade boosts GR-2’s adaptability, making it capable of handling a broader range of challenges, such as long-distance walking.
Engineering Breakthroughs for Developers
GR-2 features integrated cabling design for power and communication transmission, allowing concealed wires and more compact packaging. The efficient layout optimizes space for easier modularization and greater adaptiveness for application-oriented customization.
To simplify the control system and reduce maintenance, Fourier re-designed GR-2’s joint configuration, shifting from a parallel to a serial structure. It improves debugging, lowers manufacturing costs, and enhances the robot’s ability to rapidly learn and transition from AI simulation to real-world applications.
12-Degrees-of-Freedom Dexterous Hands: Precision in Motion
GR-2 introduces 12-DoF dexterous hands—double the dexterity of previous models. Designed to mirror the flexibility of human physiology, these hands adapt seamlessly to complex tasks with greater precision.
Equipped with six array-type tactile sensors, GR-2 can sense force, identify object shapes and materials, and adjust its grip in real time for optimal manipulation in dynamic settings.
Supporting multiple upper-limb teaching modes—VR remote control, lead-through programming, and direct command—GR-2 can record a comprehensive set of operational data, from motion paths to tactile responses. The robust data collection expects to bridge the gap between virtual models and real-world applications, pushing the boundaries of robot training and deployment further.
FSA 2.0: Powering Dynamic Mobility
Fourier breaks new ground in humanoid robotics by incorporating human-like motion into GR-2’s design. To optimize its movement, the company developed seven distinct FSA actuators for GR-2, each tailored to meet the specific torque demands of every joint.
With peak torques exceeding 380 N.m, FSA 2.0 boosts GR-2’s agility and dynamic capabilities. The dual-encoder system doubles control accuracy, ensuring precise movements even in high-pressure environments. Designed for both speed and precision, FSA 2.0 empowers GR-2 to navigate complex tasks with greater flexibility.
Optimized Tools for Innovative Development
Fourier prioritizes the developer’s experience. The company optimized GR-2’s development platform by introducing a new software development kit compatible with mainstream programming languages such as ROS. Developers can have easy access to a robust suite of pre-optimized modules for machine vision, path planning, and force feedback control through intuitive APIs. 
Supporting frameworks such as NVIDIA Isaac Lab and Mujoco, the new platform empowers developers to focus on innovation, streamlining their workflow and elevating the robotics development experience.
“GR-2 is a big step into the future of humanoid robotics,” said Alex Gu, CEO of Fourier. “We’re passionate about building the most intuitive embodied agent for AI, allowing it to engage with the physical world in ways like never before. Fourier is excited to have developers, researchers, and enterprises join us on this incredible journey.”
Fourier GRx series sets new standards in humanoid robotics with its emphasis on AI integration. In view of the future evolution of humanoid robot entities, the company outlines six key areas for development—locomotion, manipulation, cognition, bionic design, user experience, and commercial viability. The launch of GR-2 marks a new step toward future breakthroughs in human-robot collaboration.
About Fourier
Founded in 2015, Fourier is a leading general-purpose robotics company. At Fourier, our mission is to leverage full-stack robotics technology to enrich people’s lives. We’re headquartered in Shanghai, China with a team of over 500 employees globally. For more information about Fourier, please visit: www.fftai.com.  
Photo – https://mma.prnewswire.com/media/2518296/GR_2.jpgPhoto – https://mma.prnewswire.com/media/2518297/GR_2__________1.jpgPhoto – https://mma.prnewswire.com/media/2518298/FSA_Actuators.jpgPhoto – https://mma.prnewswire.com/media/2518299/Fourier_GRx_Series.jpg

View original content:https://www.prnewswire.co.uk/news-releases/fourier-unveils-the-next-generation-humanoid-robot-gr-2-302262432.html

Continue Reading

Trending